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Abstract
The human microbiota functions at the interface between diet, medication-use, lifestyle, host immune development and 
health. It is therefore closely aligned with many of the recognised modifiable factors that influence bone mass accrual in the 
young, and bone maintenance and skeletal decline in older populations. While understanding of the relationship between 
micro-organisms and bone health is still in its infancy, two decades of broader microbiome research and discovery supports 
a role of the human gut microbiome in the regulation of bone metabolism and pathogenesis of osteoporosis as well as its 
prevention and treatment. Pre-clinical research has demonstrated biological interactions between the microbiome and bone 
metabolism. Furthermore, observational studies and randomized clinical trials have indicated that therapeutic manipulation 
of the microbiota by oral administration of probiotics may influence bone turnover and prevent bone loss in humans. In this 
paper, we summarize the content, discussion and conclusions of a workshop held by the Osteoporosis and Bone Research 
Academy of the Royal Osteoporosis Society in October, 2020. We provide a detailed review of the literature examining the 
relationship between the microbiota and bone health in animal models and in humans, as well as formulating the agenda 
for key research priorities required to advance this field. We also underscore the potential pitfalls in this research field that 
should be avoided and provide methodological recommendations to facilitate bridging the gap from promising concept to a 
potential cause and intervention target for osteoporosis.
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Introduction
This viewpoint article summarizes current knowledge in 
the microbiome field and identifies research priorities to 
advance microbiome research in osteoporosis and bone 
health. Most of the studies in this field have focussed on 
analysis of the microbiome content of faeces or stool sam-
ples which are considered to represent the gut microbiome. 
Therefore, within this article we will use the broad term “gut 
microbiome” to describe this research while acknowledging 
that there is actually very little information on the microbi-
ome content in different parts of the intestine. The overall 
goal is to improve our current understanding of the rela-
tionship between the microbiome and bone health, and to 
translate this knowledge into actionable recommendations 
to prevent the development of osteoporosis or to find a cure 
for patients with this condition.
The Gut Microbiome and Osteoporosis: An Appetite 
for Discovery and Translation
It has been estimated that nine million fragility fractures 
occur worldwide each year, which are associated with 
significant morbidity and mortality [1–3]. The therapeu-
tic options for osteoporosis that reduce fracture risk have 
expanded as anabolic agents have become available [4, 5]. 
Despite this, primary and secondary fracture prevention 
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remains sub-optimal [6]. The reasons for this are multi-
factorial but include fear of adverse effects of medication 
and poor co-ordination of healthcare systems [7–9]. A fre-
quent question asked by patients is; “are there any supple-
ments, changes in diet or lifestyle change that I can make 
instead of taking drugs?” [10].
Over the last two decades, the development and avail-
ability of high-throughput next-generation genome 
sequencing technologies has facilitated the characteriza-
tion of the array of micro-organisms that reside within 
the human intestine, known as the gut microbiota. Our 
understanding of the collective genome of these microbes, 
known as the gut microbiome, is ever-expanding. It is now 
well-established that the composition, and in many cases, 
the functional potential and metabolic activity of the gut 
microbiome is heavily influenced by factors such as diet 
[11], medication use with drugs such as glucocorticoids 
and broad-spectrum antibiotics [12, 13], as well as frailty 
and ageing [14]. Co-incidentally, many of these variables 
also contribute to the pathogenesis of osteoporosis (Fig. 1) 
[15]. Whilst well-established mechanisms exist to explain 
how these factors affect fracture risk, it is pertinent to 
explore the influence that the gut microbiome may have 
both directly on bone architecture and metabolism, and 
indirectly through its interactions with ‘traditional’ risk 
factors for osteoporosis.
Historically, the relationship between the gut microbiota 
and bone health has received scant attention in the litera-
ture. However, in less than five years, mechanistic studies in 
animals have progressed to association studies in humans; 
and onwards to clinical trials of the effects of probiotics in 
women with reduced bone mineral density (BMD) [16–19]. 
The acceleration in microbiome research in bone metabo-
lism is not unique since interest has increased exponentially 
across many other medical specialties. Exploring the influ-
ence of the microbiota on bone health provides a novel and 
exciting means of advancing our understanding of the patho-
genesis of osteoporosis and potentially unearthing new pre-
ventative and therapeutic targets.
Fig. 1  Contributing factors that influence the development of the gut microbiota and the pathogenesis of osteoporosis. While many factors influ-
encing the microbiome and development of osteoporosis overlap, the effects of others are unknown or are under active investigation
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Knowledge to Date: Animal Studies
A new term of osteo-microbiology was introduced for the 
rapidly emerging research field of the role of the gut micro-
biota in bone health [20]. Much of the interest stemmed 
from initial findings in murine studies [21]. The available 
literature may be broadly compartmentalized across three 
categories of animal studies; Germ-free (GF) murine stud-
ies; antibiotic/probiotic/prebiotic intervention studies; and 
models of postmenopausal osteoporosis.
Germ‑Free (GF) Murine Models
One of the earliest studies, by Sjogren et al. demonstrated 
that mice raised in GF environments, who therefore lack a 
gut microbiota, exhibited higher trabecular bone mass and 
reduced osteoclastic activity compared to conventionally 
raised mice [22]. Furthermore, repopulation of the gut of 
the GF mice with microbiota from the distal intestine of 
conventionally-raised mice led to a normalization in bone 
mass. This suggests that the presence of the gut microbiota is 
required for normal osteoclastic activity. Further studies by 
this group demonstrate that the ability of the gut microbiota 
to increase osteoclastogenic RANKL and TNF-α activity in 
bone is dependent on Nod-like receptors NOD1 and NOD2 
in the host [23]. NOD-like receptors are pattern recogni-
tion receptors, representing a critical component of innate 
immunity, supporting the hypothesis that the gut microbiota 
may affect bone turnover in an immune-mediated manner.
Whilst an increase in bone mass in GF mice has been 
replicated by others [24], the degree of reduction or normali-
zation of bone mass in GF mice following reconstitution of 
the intestine with micro-organisms has not been consistent 
across all investigations. A study by Quach et al. did not 
identify significant change in trabecular bone volume in GF 
mice reconstituted with faeces from human vegetarians and 
omnivores, nor with caecal microbiota from convention-
ally raised mice [25]. The authors of this study highlight 
the genetic make-up of the mouse model and selection of 
donor microbial communities as key considerations that may 
influence the outcomes on bone health following microbial 
colonization of GF animals.
GF mouse models have also been used to investigate the 
mediators of microbiota-dependent bone mass regulation. 
Two separate studies in GF mice have implicated the produc-
tion of short chain fatty acids (SCFA) such as butyrate and 
acetate by the gut microbiota as an important mediator of 
bone formation [26, 27]. Based on their work in GF CB6F1 
mice, Yan and colleagues propose that anabolic effects on 
bone following chronic colonization of GF mice (8 months) 
with a pathogen-free microbiota are possibly mediated 
by insulin-like growth factor 1 (IGF-1) production [27]. 
Additionally, antibiotic treatment of conventionally raised 
mice led to a reduction in circulating IGF-1 and concurrent 
inhibition of bone formation. Provision of SCFA to mice 
who received antibiotics restored IGF-1 and bone mass to 
levels present in mice that were not treated with antibiot-
ics. The potential of microbial-derived SCFA, in particular 
butyrate, to mediate bone formation was further supported 
in another GF and antibiotic-treated mouse study [26]. Here, 
the anabolic effects of parathyroid hormone (PTH) were 
dependent on an intact microbiota. Strikingly, nutritional 
supplementation of butyrate in antibiotic-treated mice led to 
restoration of the ability of daily PTH injections to stimulate 
bone formation and increase trabecular thickness.
Antibiotic‑Intervention Studies
Antibiotics are an established effector of the human gut 
microbiome and when not used judiciously, can have del-
eterious effects on host health, including life-threatening 
infection with Clostridioides difficile.[28, 29] The long-term 
sequelae of early-life consumption of antibiotics is the sub-
ject of much interest. In the preterm infant, antibiotic use 
can lead to reduced intestinal species diversity and richness, 
in addition to long-lasting carriage of multi-drug resistant 
organisms [30]. Association studies indicate that antibiotic 
use in childhood increases the risk of developing atopy and 
autoimmune inflammatory disorders such as juvenile idio-
pathic arthritis and rheumatoid arthritis in later life [31–33].
Studies in rodents have revealed that repeated depletion 
of the gut microbiota in early life by pulsed oral intake of 
broad-spectrum antibiotics can lead to increased bone min-
eral content and BMD [34]. The authors suggest that the 
increased BMD observed in mice receiving the widely used, 
broad-spectrum beta-lactam, amoxicillin, may be due to a 
greater abundance of oxalate-degradation genes present in 
the gut microbiome post-antibiotic treatment. A reduction 
in levels of oxalate, a major calcium-binding anion in the 
intestinal lumen, could facilitate a greater availability and 
absorption of calcium from the intestines, enhancing bone 
mineralisation. This theory was supported by the presence of 
lower levels of oxalate in the faecal matter of mice receiving 
amoxicillin.
Another potential mechanism by which alteration of 
the gut microbiome may affect bone health relates to the 
microbial synthesis and luminal availability of vitamin  K2 
(menaquinone). Warfarin, the widely used vitamin K antago-
nist, has long been associated with a small increase in the 
risk of osteoporotic fractures in adults [35, 36]. While vita-
min K can affect bone quality through several mechanisms, 
the presence of vitamin K-dependent γ-carboxyglutamic 
acid residues is crucial for osteocalcin production and bone 
formation [37]. Using a metagenomic-based sequencing 
approach, Guss and colleagues demonstrated that disruption 
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of the gut microbiota of C57BL/6 J inbred mice by broad 
spectrum antibiotics (ampicillin and neomycin) led to a 
reduced abundance of vitamin K-producing genes within 
the gut microbiome (MenB, MenC, MenG). This resulted in 
a subsequent deterioration in bone mineral crystallinity.[38] 
Their work was supported by the finding of reduced avail-
ability of menaquinone within the intestine, liver and kidney 
of the antibiotic-treated mice. This study provides an excel-
lent example of how metagenomic sequencing, combined 
with metabolite quantification in biological samples, can 
provide valuable insight into functional metabolic capacity 
and activity, allowing us to understand how the gut microbi-
ome can affect processes relevant to bone health.
Models of Postmenopausal Osteoporosis
To investigate whether the gut microbiome plays a role in 
the pathogenesis of postmenopausal osteoporosis, GF mice 
studies have frequently been used in combination with ova-
riectomy or with oestrogen deficiency induced by gonado-
trophin-releasing hormone analogues (GnRH).
One of the more striking examples of this is provided by 
Li et al. [24] This study demonstrated that upregulation of 
osteoclastogenic cytokines in the bone marrow (IL-17, TNF-
α, and RANKL) and trabecular bone loss did not occur in 
GF mice in response to oestrogen deficiency but did occur 
in conventionally raised mice [24]. This was supported by 
two other studies in ovariectomized rats, where perturba-
tion of the indigenous microbiota with doxycycline attenu-
ated sex steroid deficiency-induced changes in bone mineral 
content and mechanical properties [39, 40]. Furthermore, 
in the study of Li and colleagues, twice-weekly probiotic 
supplementation of the indigenous microbiota of sex-steroid 
deficient mice with Lactobacillus rhamnosus provided pro-
tection against bone loss, whereas supplementation with a 
non-probiotic strain of Escherichia coli did not.
Lawenius and colleagues have examined the effects of a 
novel probiotic, pasteurized Akkermansia muciniphila, on 
ovariectomy-induced bone loss [41]. This mucin-degrading 
micro-organism provides an attractive option as a next-
generation probiotic [42]. It is known to improve barrier 
function in the gut, has led to improved metabolic status in 
mice and its abundance is inversely associated with obesity 
and associated with the degree of athletic fitness in humans 
[43–45]. In the ovariectomized mouse model, supplementa-
tion with A. muciniphila for four weeks led to reduced fat 
mass accumulation, mirroring previous studies. However, 
in comparison to mice who received sham surgery, probi-
otic treatment did not confer any protective benefit on bone 
health. Specifically, A. muciniphila reduced bone mass in 
gonadal-intact mice who underwent sham ovariectomy but 
did not attenuate bone loss in ovariectomized mice.
In summary, the data from animal studies provide evi-
dence to support a role of the gut microbiome on the regu-
lation of bone mass attainment and bone remodelling. The 
evidence also suggests that some of the effects of oestrogen 
deficiency on bone health are microbiota-dependent. The 
effects of microbiota alteration or depletion by antibiotics is 
less consistent and requires further study. However, caution 
is needed when attributing direct causation to the effects 
of specific microbes or microbial communities to bone for-
mation or resorption. This is particularly true of GF ani-
mal studies, since these conditions cannot be replicated in 
humans and are not directly translatable [46].
Knowledge to Date: Human Studies
Human Observational Studies
Several observational studies examining the relationship 
between BMD and the gut microbiota have recently been 
published [17, 47, 48]. All of these have used 16 s ribosomal 
RNA amplicon sequencing to analyse the gut microbiota. 
The largest study, published by Das et al., [17] examined 
variation in the gut microbiota according to BMD measure-
ments in 181 adults; 60 with normal BMD, 61 with osteope-
nia and 60 with osteoporosis. The mean age of participants 
was 64 years and the cohort was predominantly female. 
Microbial diversity in the gut had previously has been show 
to correlate with frailty in elderly residents of residential 
homes [14], but did not associate with BMD in this younger 
cohort of community dwellers. A large number of potential 
confounders were recorded and after controlling for these, 
five taxa remained significantly different between the normal 
BMD and osteopenic/osteoporotic groups.
Interestingly, a study of the EPIC cohort (European 
Prospective Investigation into Cancer and Nutrition) has 
shown an association between vegan and vegetarian diets 
and fracture incidence [49]. Although the researchers did not 
specifically interrogate the effects of these diets on the gut 
microbiota, this is clearly an area of research interest given 
the increasing popularity of vegan and plant-based diets 
in young, female individuals. Furthermore, in the EPIC-
Norfolk cohort, observational analysis of the relationship 
between the Mediterranean diet and fracture incidence dem-
onstrated that greater adherence to the diet was associated 
with a significant reduction in fracture risk [50]. Although, 
it is not possible to attribute causation to this, long-term 
adherence to the Mediterranean diet is known to directly 
impact the gut microbiota with resultant health benefits for 
the host [11, 51].
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Interventional Studies
There have been several randomized controlled trials in 
humans investigating the effects of probiotic supplementa-
tion on bone health.
Nissen and colleagues performed a double-blind, pla-
cebo-controlled trial examining the effect of the probi-
otic Lactobacillus reuteri ATCC PTA 6475 on bone loss 
of women with reduced bone mass (mean age 76 years) 
[18]. This trial built upon convincing evidence from ova-
riectomized mice, where supplementation with L. reuteri 
ATCC PTA 6475 protected against bone resorption and loss 
associated with oestrogen deficiency [52]. Seventy women 
completed the study which involved taking the probiotic at 
a dose of 1 ×  1010 colony-forming units (CFU) per day or 
placebo. After one year, those receiving the probiotic sup-
plement experienced a reduced loss of volumetric BMD at 
the tibia compared to those taking placebo (mean relative 
change − 0.83% [95% CI − 1.47 to − 0.19%], vs. − 1.85% 
[95% CI − 2.64% to − 1.07%]; intention to treat analysis). 
Subsequently, the same group of authors performed a metab-
olomic-based analysis of serum samples from participants 
in both treatment groups using liquid chromatography—tan-
dem mass spectrometry to identify possible mechanisms for 
these effects. The authors identified 97 metabolites involved 
in multiple processes, including amino acid, peptide, and 
lipid metabolism which showed trends for differences 
between the treatment groups, but none remained signifi-
cant after correction for multiple testing [53]. Accordingly 
the mechanisms by which Lactobacillus reuteri affects bone 
mass remains incompletely understood at present.
The effects of Lactobacilli probiotics for improvement 
of bone health was further studied using a combination of 
three Lactobacillus strains (L. paracasei DSM 13434, L. 
plantarum DSM 15312, and L. plantarum DSM 15313) in a 
multicentre, randomized, double-blind, placebo-controlled 
trial in Sweden [19]. This trial built on evidence in ovariec-
tomized mice, where supplementation with the same mix of 
three Lactobacillus strains protected against bone loss asso-
ciated with oestrogen deficiency [54]. Early postmenopausal 
women were randomized on a 1:1 basis to combination Lac-
tobacillus probiotic at a daily dose of 1 ×  1010 CFU or pla-
cebo for 12 months. 234 randomized participants completed 
the study with the Lactobacillus probiotic recipients experi-
encing minimal loss in lumbar spine BMD over 12 months 
(mean percentage change − 0.01% [95% CI − 0.50 to 0.48]), 
whereas those receiving placebo experienced a larger reduc-
tion in BMD (− 0.72% [95% CI − 1.22 to − 0.22%]).
In a further randomised trial performed by Takimoto 
and colleagues [55], 76 healthy postmenopausal Japanese 
women were allocated to receive the probiotic Bacillus 
subtilis (C-3102) or a matching placebo for a period of 
24 weeks. There was a significant increase in total hip 
BMD of about 1.5% in the C-3102 group compared with 
the placebo group, but no significant difference in lumbar 
spine BMD. There was a trend for lower levels of the bone 
resorption markers urine NTX and serum TRAP 5b in the 
probiotic group at 12 weeks but this was not sustained at 
24 weeks. The authors also noted changes in the relative 
abundance of various gut microbiota species in the C-3102 
group compared with placebo. Consistent decreases in 
Fusobacteria species were noted at 12 and 24  weeks 
whereas the abundance of Bifidobacterium increased at 
12 weeks in the C-3102 group. This led the authors to 
speculate that the decrease in Fusobacteria and increase 
in Bifidobacterium might favourably influence bone den-
sity by decreasing production of cytokines which regulate 
bone resorption. Nonetheless the authors also pointed out 
that overall, there was no significant correlation between 
the relative abundance of individual bacterial species and 
BMD or bone turnover markers in the study population.
In another study, Lambert and colleagues [56] inves-
tigated the effects of isoflavones and probiotics on bone 
health in a randomised placebo-controlled trial involving 
85 postmenopausal women with osteopenia on DEXA with 
an average age of just over 60 years. The isoflavones and 
probiotics were delivered in the form of red clover extract 
(RCE) given twice daily for 12 months and the effects of 
this was compared with an identical placebo. The pro-
biotic component of the active intervention comprised a 
heterogeneous culture of lactic acid producing bacteria. 
Participants in both groups were given calcium (1200 mg 
daily), magnesium (550 mg daily) and calcitriol (25 mcg 
daily) throughout the study. The RCE was found to signifi-
cantly reduce bone loss at the lumbar spine, femoral neck 
and trochanter compared with placebo. In the RCE group, 
the bone resorption marker serum CTX-I was slightly but 
significantly reduced at 12 months whereas no significant 
change was detected in the placebo group. No signifi-
cant change was detected in the bone formation marker 
P1NP during the study. Serum osteoprotegerin concen-
trations increased during the study to a similar extent in 
both groups. The authors concluded that the intervention 
was effective in slowing postmenopausal bone loss over a 
12 month period but the study design did not allow them to 
determine whether it was the probiotic, the isoflavones or 
the combination of both interventions that was responsible 
for the effect observed.
Jafarnejad and colleagues [57] conducted a randomised 
placebo controlled trial of probiotics in 50 postmenopau-
sal Iranian women with osteopenia for a 6-month period. 
The probiotic intervention consisted of a capsule contain-
ing seven different strains of probiotics (four species of 
Lactobacillus, two species of Bifidobacterium and one 
of Streptococcus thermophilus). The authors measured 
changes in spine and hip BMD as well as a large number 
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of biochemical markers of bone metabolism at baseline 
and at 6 months. No significant changes in BMD were 
observed in either group. There were nominally signifi-
cant falls from baseline in serum TNFα, bone specific 
ALP, CTX and PTH in the probiotic group compared with 
placebo groups from baseline, analysed by ANCOVA, 
but no correction for multiple testing was applied. The 
authors concluded that probiotics may have reduced bone 
turnover and production of the pro-inflammatory cytokine 
TNFα which also acknowledging that the sample size was 
small and the duration of the study relatively brief.
In summary, the available evidence suggests that probi-
otic supplements can attenuate bone loss in postmenopau-
sal women, although the studies investigating this have 
been short term and individually have had small sample 
sizes. Moving forward, it will be important to conduct 
larger scale studies to evaluate if the skeletal response dif-
fers with different types of probiotic and also to determine 
of the effects are sustained in the longer term. Few human 
studies have examined the effect of dietary manipulation 
of the gut microbiota on bone health. However, candidate 
nutrients such as fibre and isoflavones have been identi-
fied as potential effectors [56, 58].
Vitamin D and the Microbiome
Vitamin D receptors are highly expressed within the 
gastrointestinal tract, particularly in the small intestine 
and colon [59]. However, expression may be reduced in 
disorders associated with reduced gut microbiota diver-
sity such as inflammatory bowel disease [60]. In a recent 
cross-sectional analysis of 567 older men, serum levels 
of calcitriol, the active hormone of vitamin D accounted 
for between 2 and 5% of the variance in the microbial 
diversity in the gut [61]. This investigation identified 
eight specific taxa, many from the phylum Firmicutes, 
that positively correlated with levels of calcitriol. Fur-
thermore, participants with higher levels of circulating 
calcitriol were more likely to have a microbiota associated 
with SCFA production (butyrate), suggesting that the gut 
microbiota may influence vitamin D bioavailability.
It has been postulated that probiotics exert a role in 
increasing circulating 25-hydroxyvitamin D. A rand-
omized controlled trial of 9-weeks of supplementation 
with Lactobacillus reuteri (NCIMB 30,242) in healthy 
participants led to a 25% increase in serum 25-hydroxy-
vitamin D in those receiving the supplement [62]. Con-
versely, a small, randomized controlled trial examining 
dose response of oral vitamin D supplementation in 20 
adults with vitamin D deficiency demonstrated differen-
tial, dose-dependent increases in the relative abundance 
of Bacteroides after 8 weeks of supplementation [63].
The existing evidence suggests that the gut microbiome 
and probiotics may alter vitamin D metabolism within the 
gut, but research also indicates that increased oral vitamin 
D intake may affect the composition of the gut microbi-
ota. Both these possibilities require further investigation 
given the widespread nature of vitamin D insufficiency 
in all age groups of the UK population.[64]
Future Directions
During the Royal Osteoporosis Society workshop, invited 
experts in the areas of osteoporosis, nutrition and microbi-
ome research discussed the key knowledge gaps in the area 
of microbiome research as it applies to bone metabolism and 
osteoporosis. Specifically, the group considered the popula-
tions of interest, the key clinical questions to be addressed 
and the study designs that might be employed to advance the 
field (Table 1). A need for prospective, longitudinal observa-
tional studies was identified since both bone health and the 
gut microbiome are subject to temporal changes across the life 
course and the relationship between them at critical junctures 
of development and physiological change needs to be investi-
gated (puberty, illness, menopause, frailty; see Fig. 2).
It is also known that, as for many other complex traits, the 
inter-individual variability in microbiota composition is partly 
under genetic control, and the first such genetic factors have 
now been identified by work of the MiBiogen consortium [65]. 
This is the first global collaboration of various microbiome 
research groups to establish more harmonized procedures to 
combine and analyse microbiome data from different sources. 
This genetic analysis will lead to a better understanding of 
which biological factors and pathways are controlling origin, 
maintenance and perturbations in the microbiome population. 
In addition, genetic factors have been identified by Genome-
Wide Association Studies for many of the physiological vari-
ables associated with microbiota composition. This opens up 
the possibility to perform Mendelian Randomization studies 
to distinguish causal effects from associations arising due 
to confounding, and to inform intervention studies based on 
nutrition, lifestyle or therapeutics such as anti-, pro- or pre-
biotics [66–68].
There are many unknowns about the effects of therapeuti-
cally administered microbes on bone. While it is important to 
investigate these effects, it is also salient to understand how 
factors such as nutrients (for example wholegrain foods and 
fibre), dietary patterns (for example vegetarian, vegan and 
mediterranean diets), medication and antibiotic use, as well 
as medical co-morbidities, may predispose to osteoporosis 
by exerting impact on the gut microbiome. Research in the 
microbiome field so far suggests that ‘making a good microbi-
ome bad’ (for example by adopting a Westernized diet) is a lot 
easier than ‘making a bad microbiome good.’ This underlines 
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the importance of advancing our knowledge of the impact of 
early life on development of the gut microbiome in relation to 
bone health.
Design of Clinical Studies
The research priorities identified for progression of microbi-
ome-osteoporosis research highlight a clear need for large, 
prospective observational studies with long-term follow-
up. To expedite this research, utilization of existing cohorts 
may provide some of the required answers but in some cases 
microbiome data may not have been collected. Cohorts such 
as UK-BIOBANK and the Avon Longitudinal Study of Par-
ents and Children (ALSPAC) in the United Kingdom repre-
sent large, well-established longitudinal databases that could 
be useful. For interventional clinical trials that manipulate 
the microbiota with the intent of host benefit, a follow-up 
time of less than 6 to 9 months is unlikely to generate use-
ful data, such is the time it takes for persistent, meaningful 
changes to be enacted upon the adult microbiota. In stud-
ies aiming to prevent complications of osteoporosis such as 
fractures it remains unclear what the best suggorate measure 
should be as primary outcomes in clinical trials. Regardless 
of the chosen primary outcome, we suggest that such studies 
Table 1  A list of potential research questions to understand the impact of the gut microbiota on bone health and osteoporosis
IBD inflammatory bowel disease, IBS irritable bowel syndrome, JIA juvenile idiopathic arthritis, BMD bone mineral density, PBM peak bone 
mass, DASH dietary approaches to stopping hypertension
Question of interest Possible mechanism of investigation
1 Are nutrition and lifestyle effects on the gut microbiota in early life 
(birth to adolescence) related to peak bone mass (PBM) attainment?
Longitudinal cohort study
2 Are nutritional and lifestyle effects on the gut microbiota in early life 
(birth to adolescence) related to risk of osteoporosis in adulthood?
Longitudinal cohort study
3 Are the effects of early-life antibiotic exposure (birth to adolescence) 
on the gut microbiota related to PBM accrual and/or bone mineral 
density in later life?
Longitudinal cohort study
4 What are the effects of childhood illness on the development of a 
healthy gut microbiota and how does this affect PBM attainment 
and risk of osteoporosis in adulthood?
Case control studies, longitudinal cohort study
5 Can the negative impact of inflammatory diseases in childhood such 
as IBD, asthma, JIA on adult bone health be attenuated by manipu-
lating the gut microbiota through diet, and pro- or prebiotic use?
Targeted exploratory and intervention studies in patient populations
6 Will recent changes in dietary habits such as vegan diets and gluten 
free diets in non coeliac individuals in younger generations affect 
future BMD and does this operate through alteration of the gut 
microbiota?
Case–control studies, Longitudinal cohort study
7 Can BMD loss be attenuated by the use of targeted dietary modifica-
tion or supplementation with pre- or probiotics during the peri-
menopausal time-span?
Clinical trials
8 Can a patient’s gut microbiota influence the individualized response 
to medications such as bisphosphonates, PTH, calcium and vitamin 
D supplements?
Prospective observational study (1–5 year duration)
9 Is the increased osteoporosis risk evident in underweight individuals 
mediated by the gut microbiota?
Longitudinal cohort study
10 How does the gut microbiota affect the availability and absorption of 
calcium, vitamin D and other mineral nutrients such as magnesium 
from the gut lumen?
Experimental animal and human studies
11 Can a specific or complex dietary modification such as an increased 
fibre, protein intake, Mediterranean or DASH diet, prebiotic or 
probiotic-use improve bone mineral density and at what stage in the 
lifecourse is the greatest benefit seen?
Clinical trials with long-term follow-up
12 Can short chain fatty acid supplementation (directly or via increased 
non-starch polysaccharide intake) improve BMD and if so, at what 
stage of the life-cycle?
Clinical trials
13 Is the reduction in BMD evident in the frail and elderly directly 
related to the concurrent decrease in gut microbial diversity that 
occurs in later life?
Cross-sectional, case–control studies, longitudinal cohort study
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incorporate a minimum of 12-month participant follow-up 
as has been performed previously [19].
Many microbiome studies suffer from low statistical 
power, lack of replication and use of variable technologies 
to assess the microbiome. Studies with low sample sizes 
often represent pilot investigations, that under ideal circum-
stances may identify strong microbiome-phenotype correla-
tions, but lack replication in independent settings or in larger 
cohorts. Interventional studies often recruit several hundred 
participants [11]. Very large microbiome studies, such as 
the American Gut Project (> 10,000 participants) [69], have 
the benefit of limiting technical variability as samples are 
usually treated uniformly, and the effects of confounding 
variables can be adjusted for in statistical models. Very large 
cohort studies may also facilitate the finding of ‘a needle in 
a hay-stack,’ increasing the probability of finding microbial 
effects that are not apparent amongst the noise of studies 
with smaller sample sizes [70]. Emphasis should be placed 
on replication of findings and this should be pursued through 
collaboration and replication cohorts, especially in the case 
of studies with smaller sample sizes.
An important consideration for all studies on the human 
gut microbiota, in particular association or interventional 
studies aimed at altering the characteristics of the micro-
biota, relates to the many confounding factors than can affect 
its composition and function. This highlights the impor-
tance of collecting data on key clinical variables that may 
directly affect the microbiota. These include recent antibi-
otic use, previous gastrointestinal surgery or illness, current 
medication use, smoking, alcohol intake, habitual intake of 
macro- and micro-nutrients, dietary supplementation, BMI 
and menopausal status. Adjustment for and consideration 
of these confounders underlines the importance of quali-
fied biostatistical expertise and collection of sufficient and 
accurate metadata [71]. The availability of rich, linked meta-
data to microbiota sequences in data repositories is crucial 
to facilitate integrative, multi-study analysis across inter-
national groups and study population cohorts. We would 
encourage research groups to collect and submit detailed 
metadata and to make them available in a FAIR manner 
(Findable, Accessible, Interoperable, Re-usable).
Technical Methodologies
Choice of technology to assess the microbiota composition 
and function is another critical consideration in microbi-
ome research. Over the last 5 years, there has been a shift 
from compositional microbiome analysis using quantitative 
PCR and 16S rRNA sequencing. While 16S sequencing is 
especially useful for large-scale profiling of microbiome 
samples because of its low cost and robustness, the desire 
to increase our understanding of pathophysiology, has seen 
a move towards shotgun metagenomic sequencing that pro-
vides information on gene content and therefore functional 
“potential” of the microbiome. True functional insights can 
only be obtained by a combination of metagenomic analysis 
of the gut microbiome with other ‘omic technologies such as 
transcriptomics, proteomics or metabolomics, in combina-
tion with intervention studies and Mendelian Randomization 
studies.
While it may seem obvious, it is noteworthy to highlight 
the importance of standardized procedures at many levels 
in microbiome research. This begins with faecal sample 
Fig. 2  Trajectory of bone min-
eral density and gut microbiota 
diversity across the life course. 
The trajectory of bone mass 
throughout life is similar in 
many respects to changes in 
diversity of the gut microbiota 
throughout the lifespan with the 
greatest changes occurring dur-
ing infancy and adolescence
Role of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis 
1 3
collection and storage methods, as these processes can 
affect apparent microbiota composition and the ability to 
accurately use additional ‘omic technologies. Early con-
sultation and collaboration with experienced biostatisti-
cians and assuring availability of the appropriate software 
and bioinformatic pipelines are all essential components. 
For a more in-depth overview and further guidance, read-
ers are directed to the referenced articles by Allaband et al. 
and Knight et al.[72, 73]
With respect to dietary assessment, the ideal and most 
accurate method for habitual dietary recording has long 
been debated (such as a 7-day food diary vs. semi-quan-
titative food frequency questionnaire). Like other recom-
mendations in this section, the choice of dietary assess-
ment tool depends on the hypothesis under investigation; 
the level of quantification required (frequency of food 
intake versus mass quantity of food); cost; time expended 
and use of the most accurate assessment tool within the 
context of the study design. Some research has suggested 
different dietary assessment methods capture distinct areas 
of diet-microbiome interaction, potentially arguing against 
a reliance on a single dietary tool [74]. The introduction 
of app- and web-based methods of dietary assessment, as 
well as emerging innovations in food image recognition 
and wearable technologies, promises to reduce participant 
burden and facilitate richer and more accurate dietary 
assessment. Depending on the research question at hand, 
it may be appropriate to consider methods for adjusting 
for total energy intake and energy under/over-reporting.
Concluding Remarks
Understanding of how food and nutrition affect life pro-
cesses is fundamental to improving health and prevent-
ing disease. With an increasing societal awareness of the 
gut microbiota and the continued emphasis on the impact 
of food and lifestyle on health, the complex interplay 
between nutrition, the gut microbiome and bone health is 
of interest to many. Methods of analysing the gut micro-
biome have advanced and are now well-positioned for us 
to investigate the mechanisms by which modern lifestyle, 
diet and illness exert their effects on bone health via the 
gut microbiome. Microbiome research offers exciting pros-
pects for patients with osteoporosis. We believe the next 
decade will provide significant progress in this new field 
of osteo-microbiology.
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